CELF4 and cardiomyopathy: The CELF4-rs1786814-GG genotype was associated with an increased risk of cardiomyopathy compared to GA and AA genotypes (p = 0.006), and when exposed to doses lower or equal to 300 mg/m2, patients carrying GG genotype were at 5.8-fold higher risk of developing cardiomyopathy compared to GA and AA genotypes [27].